Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Sales (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Return on Sales data on record, last reported at 2.47% in Q4 2025.

  • For Q4 2025, Return on Sales fell 16.0% year-over-year to 2.47%; the TTM value through Dec 2025 reached 1.7%, down 6.0%, while the annual FY2025 figure was 1.65%, 2.0% up from the prior year.
  • Return on Sales reached 2.47% in Q4 2025 per INM's latest filing, down from 1.54% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.15% in Q2 2023 and bottomed at 16.16% in Q4 2021.
  • Average Return on Sales over 5 years is 4.58%, with a median of 1.93% recorded in 2023.
  • Peak YoY movement for Return on Sales: soared 1514bps in 2023, then tumbled -136bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 16.16% in 2021, then surged by 72bps to 4.47% in 2022, then skyrocketed by 73bps to 1.19% in 2023, then tumbled by -94bps to 2.32% in 2024, then fell by -7bps to 2.47% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 2.47% in Q4 2025, 1.54% in Q3 2025, and 1.37% in Q2 2025.